Home

RECIST 1.1 calculator

The guidelines. The revised RECIST guidelines (version 1.1) are available here for free with permission from the European Journal of Cancer (EJC). The guidelines and accompanying articles were published in a special issue of EJC in January 2009. guidelines Download RECIST 1.1 Calculator - This application allows evaluation of solid tumor response to chemotherapy according to the most recent RECIST 1.1 guidelines. Target definition rules at baseline are reminded. The calculator provides the sum of.. RECIST 1.1 is a standard way to measure the response of a tumor to treatment. In this article we will discuss the basics of RECIST. The criteria to determine whether a tumor disappears, shrinks, stays the same or gets bigger are complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)

RECIST 1.1 Calculator (Package Name: appinventor.ai_louis_lassalle.RECIST_1_1_Calc) is developed by Louis Lassalle and the latest version of RECIST 1.1 Calculator 1.0 was updated on September 18, 2014. RECIST 1.1 Calculator is in the category of Medical. You can check all apps from the developer of RECIST 1.1 Calculator RECIST 1.1 - the basics. Fokko Smits, Martijn Dirksen and Ivo Schoots. Radiology Department of the Erasmus MC in Rotterdam and the Isala hospital in Zwolle, the Netherlands. RECIST 1.1 is a standard way to measure the response of a tumor to treatment. In this article we will discuss the basics of RECIST. The criteria to determine whether a.. This application allows evaluation of solid tumor response to chemotherapy according to the most recent RECIST 1.1 guidelines.Target definition rules at baseline are reminded.The calculator provides the sum of diameters, as well as the percentage of variation from the reference study. Based on the probabilities derived from the simulation, we developed an algorithm to evaluate the reliability of an ORR (or progression rate) (i.e., the variation in the assessed rate) by generating a 95% central range of ORR (or progression rate) results if a reassessment was performed. Finally, we performed validation using an external dataset Recist 1.1 calculator worksheet xls Keyword Found Keyword-suggest-tool.com DA: 28 PA: 44 MOZ Rank: 73 Features of the RECIST 1.1 calculator version 1.0 beta: Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable diease when the change is > -30% and ≤ 20%, partial response when there is a decrease

Recist 1.1 - Recis

RECIST 1.1. Measurable Disease at BL. Required, MTLS. When required then MTLS, Pats. with non-measurable disease only are allowed. Minimum Target Lesion Size. ≥10 mm (Spiral CT) ≥20 mm (Conventional CT, MRI) ≥10 mm (CT + MRI) ≥15 mm Lymph nodes RECIST 1.1 - Adapting and updating guidelines to improve the assessment of outcomes. By pruyskart June 24, 2016. Hear Larry Schwartz summarize the latest work from the RECIST Working Group. One focuses on clarifying the interpretation of RECIST 1.1, and one provides a summary of current widely accepted alternatives to RECIST in certain. Calculate timepoint response. Measurable Lesions. Tumor ≥10 mm in longest diameter (LD) on an axial image on CT or MRI. Lymph nodes ≥15 mm in short axis on CT. Lymph node measurements: specific instructions: short axis ≥15 mm is measurable. RECIST 1.1 Last modified by WHY ENHANCE RECIST 1.1 In some cases, RECIST 1.1 is open to interpretation as it does not give every detail needed to properly assign BOR. For example, as one can see from Display 1: (CR - CR) In a study with CR confirmation of 4 weeks, for a patient with CR-CR-PD on Days 7, 21, 35, RECIST 1.1 concludes the BOR is CR RECIST 1.1 Guidelines RECIST 1.1 Guidelines Measurable Tumor Burden A maximum of 10 target lesions in total (and u pt o5 er rgan) ca nbe i de tifie at baseline and measured through the course of therapy. A maximum of 5 target lesions in total (and up to 2 per org an) c n be identified t baseline and measured through the course of therapy

RECIST 1.0 and 1.1. • Discuss how to use target and non-target lesions when determining overall response for RECIST 1.0 and 1.1. • Define what is meant by a partial response for RECIST 1.0 and 1.1. RECIST is being used in most of the CCR's solid tumor protocols to assess tumor response. However, not all studies will be using RECIST • Solid Tumor -RECIST 1.1 • Lymphoma - Cheson 2007 or IWCLL 2008 • Leukemia - Study specific Oncology Study 10/16/2013 Cytel Inc. 5 • RECIST(Response Evaluation Criteria in Solid Tumor) • Version 1.0 and 1.1 (released on October 2008) • Lesions.

RECIST 1.1, published in January 2009, is an update to the original criteria. Today, the majority of clinical trials evaluating cancer treatments for objective response in solid tumors are using RECIST. Cancer trials are increasingly complex, involving dozens or even hundreds of investigators from centers around the world Our latest FREE demonstration tool (https://lnkd.in/dsrw42Y) for clinical trials using the RECIST1.1 framework - RECIST360-beta provides a visual tumour time.. Instruction for installing RECIST 1.1 Calculator app apk on Android devices. Step 1: Download RECIST 1.1 Calculator app apk on this page, save it to easy-to-find location. Step 2: Make sure that third-party applications are allowed on your device.Go to Menu > Settings > Security and check Unknown Sources to allow your device to install applications from sources other than the Google Play Store In RECIST 1.1, detailed instructions about how to mea - sure and assess lymph nodes are provided [2, 5]. Lymph nodes with a short axis of ≥ 15 mm are considered measurable and assessable as target lesions, and the short-axis measurement should be included in the sum of target lesion measurements in the calculation of tumor re RECIST guideline (version 1.1) in the European Journal of Cancer in 2008 (Eisenhauer E.A. et al). It is a complex paper written by many associations from across the world, which talks about how to calculate Best Response of subjects having solid tumors in a clinical tri al. Any programmer who has attempted or i

1.3. Process of RECIST 1.1 development The RECIST Working Group, consisting of clinicians with expertise in early drug development from academic research organisations, government and industry, together with imag-ing specialists and statisticians, has met regularly to set the agenda for an update to RECIST, determine the evidenc The calculator provides the sum of diameters, as well as the percentage of variation from the reference study and the overall result according to RECIST 1.1 criteria, also integrating non-target and new lesions

RECIST 1

Purpose of Review This review aims to give a brief update how to do RECIST 1.1, irRECIST 1.1, and mRECIST. Recent Findings The revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are currently representing the most commonly used and validated response criteria for objective treatment monitoring of conventional chemotherapies in solid tumors. However, with the introduction of. RECIST 1.1: comparison with RECIST 1.0. Dr Julius Rozmiarek and Dr Usman Bashir et al. Response Evaluation Criteria In Solid Tumors (RECIST) was updated to version 1.1 in 2009. For both RECIST 1.0 and 1.1, the requirement for measurable disease at baseline depends on the endpoints of the clinical trial. The fundamental concept common to both. Download RECIST 1.1 Calculator apk 1.0 for Android. RECIST 1,1 calculadora para evaluación de la respuesta a la quimioterapia de tumores sólidos RECIST 1.1 :MODE D'EMPLOI LaureS.Fournier1,2, Rokhaya Thiam1,2, Guy Frija1,2 1. Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Radiologie, 20, rue Leblanc, F-75908 Paris Cedex 15 2. INSERM, U970, Cardiovascular Research Center (PARCC), 40, rue Leblanc, F-75908 Pari Download Now. RECIST 1.1 Calculator v1.0 Apk screenshot

RECIST 1.1 Calculator - Downloa

  1. Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage. Can be accurately measured in at least one dimension as 10 mm or more (measure longest diameter). Suitable for repeat measurement. Intratumoral arterial enhancement on contrast-enhanced CT or MRI
  2. Tip1a: Stick strictly if you want to RECIST 1.1 target lesion measurement rules: number= two . What Has Changed: RECIST 1.0 - RECIST 1.1. Tumor ≥10 mm on longest diameter (LD) with an axial image with CT and MRI with.. Calculate timepoint response. Included are calculators similar to adrenal washout calculators, RECIST 1.1 and
  3. ded
  4. Try this amazing Recist 1.1 Level 1 quiz which has been attempted 135 times by avid quiz takers. Also explore over 39 similar quizzes in this category
  5. recist 1.1 calculator worksheet xls initial. 我們無法提供該頁面的具體描述。 TheBookEdition.com - Home TheBookEdition.com, Hallennes-lez-Haubourdin. 8,511 likes · 74 talking about this. Auto-édition et impression de livres à la demande depuis 2007. Publiez gratuitement votre livre au format papier o
  6. Today in this post, I'd like to make an introduction on RECIST 1.1 and then clarify on how to compute related common statistics using PROC FREQ. BOR (Best Overall Response) RECIST (Response Evaluation Criteria in Solid Tumors) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize.
  7. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to the development of a revised RECIST guideline (version 1.1)

The Radiology Assistant : RECIST 1

  1. •RECIST : Response Evaluation Criteria In Solid Tumours •Evaluation standardisée de la réponse tumorale •Critère : somme des diamètres des lésions cibles •RECIST 1.0 (2000) •RECIST 1.1 (2009) Limite à 5 lésions cibles Intègre l'analyse ganglionnaire Lésions osseuses (sous condition
  2. RECIST 1.1 RECIST 1.1은 사실 작년에 나왔는데 게을러서 정리를 못하고 있다가, 몇 가지를 정리해보고 넘어가고자 합니다. RECIST 1.0 RECIST 1.1 Measuring tumor burden Maximal 10 target lesion 5 per org.
  3. The Response Evaluation Criteria in Solid Tumors (RECIST) were published in February 2000 by the . European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group. RECIST criteria ar

Sur RECIST 1.1 Calculator. Cette application permet l'évaluation de la réponse solide de tumeur à la chimiothérapie selon les directives plus récentes de RECIST 1.1. Les règles de définition cible à la ligne de base sont rappelées. La calculatrice fournit la somme des diamètres, ainsi que le pourcentage de variation de l'étude de. Critères RECIST version 1.1 Evaluation de la réponse tumorale (Nouveaux critères RECIST v 1.1) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E.A Download RECIST 1.1 Calculator 1.0 apk for your Android (FREE). RECIST 1.1 calculadora para avaliação da resposta do tumor sólido de quimioterapia

RECIST 1.1 Calculator APK 1.0 Download for Android ..

Measurement variability calculator (RECIST 1.1) version 1.1 is released. - August 29th, 2017. Measurement variability calculator (RECIST 1.1) version 1.0 is released. - March 14th, 2017. Measurement variability calculator (RECIST 1.1) beta version is released. - March 2nd, 201 이하나, recist 1.1과 다른 차이점에 대해서 숙지가 필요 하다. 용 어 irecist는 recist 1.1을 기반으로 하며, recist 1.1 와 구별하기 위해 면역 (immune)을 뜻하는 i 라는 접 두어를 recist 1.1 용어에 덧붙여 사용한다. 예를 들어 recist 1.1 반응 기준의 용어와 구분하기 위하여. PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with TCAs. We investigated the performance of RECIST using a pooled database from 50 clinical trials with at least one TCA. METHODS We examined the impact of the number of target lesions (TLs) on within-patient. recist 1.1 criteria (1) year 2009 measurable lesions 2 per organ, maximum 5 lymph node disease short axis dimension >15 mm <10 mm ( non measurable ) 10-15 mm ( non target ) disease progression 20% increase in sum of the target lesion Circa RECIST 1.1 Calculator. Questa applicazione consente la valutazione della risposta tumorale solida alla chemioterapia secondo le più recenti linee guida RECIST 1.1. Vengono ricordate le regole di definizione di destinazione alla linea di base

Download RECIST 1.1 Calculator APK Full. RECIST 1.1 калькулятор: Response Evaluation Criteria In Solid Tumours - RECIST 1. If you are on a small screen mobile device, turn to landscape and pinch zoom to fit the table in the view. The RECIST committee does not provide a tool for calculating the response categories Table 1 Highlights of revised RECIST 1.1, summary of major changes RECIST 1.0 to RECIST 1.1: RECIST 1.0 RECIST 1.1 Number of target lesions 10 lesions, 5 per organ 5 lesions, 2 per organ Assessment of pathological lymph nodes Not mentioned Nodes with a short axis of ≥ 15 mm are considered measurable and assessable as target lesions. The short. Recist 1. RECIST GUIDELINES Dr. D. Ramu 2. • Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics. • Both tumour shrinkage (objective response) and time to the development of disease progression are important endpoints in cancer clinical trials • 1981 the World Health.

Download RECIST 1.1 Calculator APK APKfun.co

Reason tor RECIST assessment discontinuation O O O O O Specify reason Study treatment discontinuation Subject not clinically stable iCPD never occurred Patient's decision Please specify why patient decided as such, in the field below Other Please specify the reason in the field below #150 . Title: Enter Study title her The RECIST (Response Evaluation Criteria in Solid Tumors) guidelines (RECIST 1.0 and RECIST 1.1) have been the standard for response evaluation in clinical trials and have supported myriad regulatory approvals in solid tumors. RECIST first published in 20002 (v1.0) and later revised in 20093 as RECIST 1.1 provided a methodolog Hakkı -nda RECIST 1.1 Calculator. Bu uygulama kemoterapiye solid tümör yanıtının en son RECIST 1.1 kılavuzlarına göre değerlendirilmesini sağlar. Taban çizgisinde hedef tanımı kuralları hatırlatılır. Hesap makinesi, çapların toplamının yanı sıra referans çalışmadaki varyasyon yüzdesini ve RECIST 1.1 kriterlerine. with RECIST 1.1. Patients with non-measurable disease can still be included in trials where response is not the primary endpoint (eg, in trials with progression-free survival, overall survival, or other primary endpoints). For studies in which CNS objective response is the primary endpoint, we generally recommend a cutoff o RECIST 1.1 criteria. The percent change of baseline for RECIST is generally calculated as: ((VALUE2 / VALUE1) - 1) * 100 = % CHANGE In this example, VALUE1 is representative of the current Nadir, and the VALUE2 represents the current SLD. This calculation will be like the calculation applied in Section 3, percent change from baseline

RECIST 1.1 · bio.tool

RECIST terminology In order to clearly understand RECIST criteria before applying it in the clinical trials, it is important to understand some relevant terminologies. In RECIST criteria, lesion is generally used instead of tumor. The following terminologies are based on the revised RECIST guideline (version 1.1) When morphologic CT changes were considered in addition to RECIST 1.1 calculations, TTP was shorter than when using RECIST 1.1 alone (median, 5.6 months for both morphologic changes and RECIST 1.1 vs 8.9 months for RECIST 1.1 alone). Typically, few patients had new enhancement in previously hypoattenuating lesions over the course of therapy (16. Learning Objectives. Differentiate between RECIST 1.0 and 1.1. Describe the components of RECIST/tumor data. Apply how to correctly calculate disease response. Identify and predict common trends with tumor data. Use working knowledge of common trends to help develop Case Report Forms for oncology trials

Recist 1.1 calculator worksheet xls Keyword Found ..

  1. modified RECIST assessment (mRECIST). Further studies are needed to confirm the accuracy of this measurement compared with conventional gold standards such as pathologic studies of explanted livers. KEYWORDS: Hepatocellular carcinoma, RECIST, response assessment, time to progression magnetic resonance, computed tomography, AASLD-JNCI guidelines
  2. ation and defines progressive disease as at least a 20% increase in the sum of diameters of up to 5 target lesions (2 lesions/organ), taking as reference the smallest sum on study and an absolute lesion increase of at least 5 mm or the.
  3. gs for targeted immunotherapy in oncology. Using RECIST 1.1 in immunotherapy trials would lead to declaration of progressive disease (PD) too early, when the treatment effect is not yet fully evident. RECIST also neglects the importance of the 'flare effect' - pseudo-progression effect within the so-calle

RECIST 1.1 - Parexel Informatic

  1. The use of the RECIST 1.1 criteria enables an objective and reproducible assessment of the response to treatments. 21 In a recent meta-analysis by Cheng et al., 26 it was stated that the RECIST 1.1 criteria perform well in the NAC setting, predicting a pCR with pooled sensitivity and specificity values of 70% and 83%, respectively. None of the.
  2. ‎Learn about RECIST 1.1 and how it can be applied to your clinical trial. RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve (respond), stay the same (stable) or worsen (progression) during treatments
  3. recommendations for consistent application of recist 1.1 to - Parexel techniques and cancer treatments have highlighted the limitations of RECIST with spiral CT scan, RECIST 1.1 defines.. overall response status calculation. 87
  4. We hope this will be a useful tool and ease the transition to RECIST 1.1..
  5. Summary: RECIST 1.1 ! RECIST 1.1: Know better than PI or Radiologist ! Measurement (Measureable, Non-Measureable, Target, Non-Target, and LN) ! # of lesions and # per organ (5/2) ! Work with Radiologist and PI to accurately document which lesion is being followed and from baseline or best response ! When is patient SD, PR, PRO
  6. RECIST was jointly created by the National Cancer Institute of the United States, the National Cancer Institute of Canada Clinical Trials Group and the European Organisation for Research and Treatment of Cancer. It is designed to provide a clear set of criteria to evaluate the progression, stabilization or responsiveness of tumors

Es wurde entwickelt, um das RECIST 1.1-Bewertungssystem innerhalb der radiologischen und onkologischen Gemeinschaften zu fördern, Radiologen, die für die Bewertung der Tumorreaktion zuständig sind, Effizienzgewinne zu bieten und die Genauigkeit von Berichten zu verbessern. Es kann für Radiologen, Onkologen und Medizinstudenten nützlich sein RECIST 1.1 Calculator Google Play softwares disponible en téléchargement gratuit. Veuillez activer JavaScript de votre navigateur ou vous ne seriez pas en mesure d'utiliser de nombreuses fonctionnalités sur ce site

RECIS

  1. In 2009 the revised RECIST (Response Evaluation Criteria in Solid Tumours) guidelines (version 1.1) were published by the RECIST Working Group. Consistency in imaging and measurements are even more challenging. The purpose of the poster will be to increase familiarity with these guidelines and highlight the important changes from RECIST 1.0
  2. Recist Calculator Worksheet - Image Mag recist calculator worksheet: pin. Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling This figure is a semi-log plot of logs PSA (y-axis) pin. 1 Castration Resistant Prostate Cancer Charles J Ryan, MD 26 Serologic: bandana border clip art
  3. Features of the RECIST 1.1 calculator version 1.0 beta: Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable diease when the change is > -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all.
  4. Measurement variability calculator (RECIST 1.1). Contribute to repositivator/snucalc development by creating an account on GitHub
  5. RECIST: Round 5. RECISTv1.1 Module Definition. The Response Evaluation Criteria in Solid Tumors (RECIST) CRF module is used to document the questions collected when assessing the change in tumor burden as part of the clinical evaluation of cancer therapies using the RECIST guidelines
  6. es the resistances of resistors in either parallel or series, as well as the resistance of a conductor. Experiment with the voltage drop and Ohm's Law calculators, or explore hundreds of other calculators
  7. 尋找RECIST 1.1 Calculator app全球線上資料來【APP開箱王】提供各種開箱文 17筆1頁網友關注熱絡討論,GENE THERAPY: _____ _____ Caveat: Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. I have checked with sources believed to be reliable in their.

RECIST (response evaluation criteria in solid tumors) Baseline에서 종양 병변은 다음과 같이 2가지로 분류한다. 1) 계측 가능한 병변 (measurable) 최소한 한 방향으로 정확히 계측할 수 있는 병변을 말한다.. RECIST criteria were updated in early 2009 , based on an analysis of the literature and simulations from a database of > 6500 patients and > 18,000 lesions. The new version is called version 1.1 (with the previous version becoming 1.0). The main changes were to reduce the number of target lesions to be measured and take into account the specificity of lymph nodes by measuring their short axis

The continued use of RECIST 1.1 is recommended to define whether tumour lesions, including lymph nodes, are measurable or non-measurable, as well as for the management of bone lesions, cystic lesions, and lesions with previous local treatment (eg, radiotherapy; table 1).Similarly, no changes have been made to the recommendations regarding the method of measurement, although clinical. En 1999, les critères RECIST ont défini une méthode simple d'évaluation unidimensionnelle [11]. Ces critères ont été revus en 2009, sous l'appellation RECIST 1.1 [1]. Ces critères sont aujourd'hui utilisés dans l'immense majorité des essais thérapeutiques iRECIST defines iUPD on the basis of RECIST 1.1 principles; however, iUPD requires confirmation, which is done on the basis of observing either a further increase in size (or in the number of new lesions) in the lesion category in which progression was first identified in (ie, target or non-target disease), or progression (defined by RECIST 1.1. RECIST 1.1, like RECIST 1.0, assumes that all lesions are spherical and that those that respond to treatment decrease uniformly in size. Of course, actual tumors are not perfectly spherical ( 9 ). The prolate ellipsoid formula, L · W · H ·(π/6), where L is the length, W is the width, and H is the height, has been used to estimate the volume. On the other hand, both RECIST 1.1 and PERCIST 1.0 classifications of therapeutic response were concordant in 20 patients representing 60.6%. Eight patients (24.2%) had CR by RECIST 1.1 and CMR by PERCIST 1.0 (Fig. 3). Seven patients had PR by RECIST 1.1 and PMR by PERCIST 1.0 (21.2%)

RECIST 1.1 - Parexe

RECIST360 Beta (RECIST 1

Clinical trials utilizing both irRC and RECIST 1.1 to measure tumor response • 411 pts, 192 were on MK-3475 (pembrolizumab) > 28 weeks • 215 patients had either a CR, PR, or SD by RECIST and irRC • 51 patients had PD by RECIST, but had either a CR, PR, or SD by irRC Authors concluded Comparison of RECIST 1.1 and iRECIST Common Points Details RECIST 1.1 and iRECIST Definition of measurable and non-measurable lesions Same Definition of target and non-target lesions Measurement and managementof lymph nodes SUM of tumor diameter calculation Definition of CR, PR, and SD Confirmationof CR and PR in Best Overall Respons Percent changes in tumor dimension were classified using RECIST 1.1 criteria , where partial response (PR) is defined as a 30% reduction in sum of linear dimensions of target lesions compared with baseline and the absence of new lesions. Progressive disease (PD) is defined as a 20% increase in the sum of linear dimensions of target lesions, and. This is a short overview of modified RECIST 1.1 criteria which allows measurement of bone lesions. The criteria is developed by The University of Texas MD An..

iRECIST and RECIST 1.1. The tumor growth rate was calculated before and after therapy initiation. The response patterns were analyzed, and the differences in tumor response assessments of the two criteria were compared. The intra- and inter-observer variabilities of iRECIST and RECIST 1.1 were also analyzed The average MTV was calculated as 41.720 mm 3 before and 44.967 mm 3 after therapy for the same patient group. Response Evaluation Criteria In Solid Tumors (RECIST) and PET Response Criteria In Solid Tumors incompatibility was seen in seven of 36 lesions in HCC-diagnosed patients and seven of 42 lesions in patients with mCRC with thyroid cancer. The number of target lesions by RECIST 1.1 was sig nificantly lower than that by RECIST 1.0 (P<0.001). Because of new lymph node criteria, fourteen patients (3.1%) had no target lesions when adopting RECIST 1.1. RECIST 1.1 showed high concordance with RECIST 1.0 in the assessment of tumor responses (k = 0.903)

Download RECIST 1.1 Calculator app apk • App id ..

The Modified RECIST criteria we have developed were as follows. Tumour thickness perpendicular to the chest wall or mediastinum was measured in two positions at three separate levels on transverse cuts of CT scan (Figure 1B). The sum of the six measurements defined a pleural unidimensional measure Poster: ECR 2015 / C-2585 / Five applications for Android smartphones, designed to promote and facilitate the use of scientific guidelines in daily radiological practice. by: <u>L. Lassalle</u>; Paris/F aliação da metabolização da glucose pelo tumor odução do aspecto funcional na pêutica s lesõe

Page 37RECIST Pocket - Android Apps on Google Play